Banner curso interno 5

Microlearnings: Psoríase em Placas e seu Tratamento com Biológicos

  • Vídeo de apresentação do curso
    • Vídeo de apresentação do curso
  • Aula 01 - Psoríase: considerações importantes
    • Psoriasis. Lancet. 2015;386(9997):983-94 (apenas leitura)
    • Videoaula 01 - Psoríase: considerações importantes
    • Prevalence of Psoriatic Arthritis in a Large Cohort of Brazilian Patients with Psoriasis. J Rheumatol 2015;42:829-43 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
    • Psoríase: comorbidades clássicas e emergentes. An Bras Dermatol. 2015;90(1): 08-19 (apenas leitura)
    • Psoríase: novas comorbidades. An Bras Dermatol. 2016;91(1):08-16 (apenas leitura)
    • Prevalence of psoriasis in Brazil - a geographical survey. Int J Dermatol. 2017;56: e-168-e-169 (apenas leitura)
  • Aula 02 - Principais comorbidades associadas à Psoríase
    • Videoaula 02 - Principais comorbidades associadas à Psoríase
    • Position statement for the management of comorbidities in psoriasis. JEADV. 2018;32:2058–2073 (apenas leitura)
    • Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Intern Med. 2017;56(13):1613-1619 (baixável)
    • Psoriasis: to treat or to manage? Exp Dermatol. 2014;23:705–709 (baixável)
    • Psoríase: comorbidades clássicas e emergentes. An Bras Dermatol. 2015;90(1): 08-19 (apenas leitura)
    • Psoríase: novas comorbidades. An Bras Dermatol. 2016;91(1):08-16 (apenas leitura)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
  • Aula 03 - Como avaliar o paciente portador de Psoríase
    • Videoaula 03 - Como avaliar o paciente portador de Psoríase
    • Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. JEADV. 2013;27:1387-1404 (baixável)
    • Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. JEADV. 2014; 28:1661-1669 (baixável)
    • Psoríase: novas comorbidades. An Bras Dermatol. 2016;91(1):08-16 (apenas leitura)
    • Position statement for the management of comorbidities in psoriasis. JEADV. 2018;32:2058–2073 (apenas leitura)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
    • Psoríase: comorbidades clássicas e emergentes. An Bras Dermatol. 2015;90(1): 08-19 (apenas leitura)
    • From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70(1):178-86 (apenas leitura)
    • Manual de Recomendações para o Controle da Tuberculose no Brasil - Ministério da Saúde, 2ª ed, 2019 (baixável)
    • Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88-97e5 (apenas leitura)
    • Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews 2015;14:503-09 (apenas leitura)
  • Aula 04 - Classificação da gravidade da Psoríase
    • Videoaula 04 - Classificação da Gravidade da Psoríase
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1): 23–31 (apenas leitura)
    • Current severe psoriasis and the Rule of Tens. Br J Dermatol.2005;152:861–867 (apenas leitura)
  • Aulas 05 a 07 (Índices de gravidade da Psoríase: DLQI, BSA, PGA e PASI)
    • Videoaula 05 - DLQI
    • Videoaula 06 - BSA e PGA
    • Videoaula 07 - PASI
    • Validação de questionários de avaliação da qualidade de vida em pacientes de psoríase. An Bras Dermatol.2004;79(5):521-535 (baixável)
    • Current severe psoriasis and the Rule of Tens. Br J Dermatol.2005;152:861–867 (apenas leitura)
    • The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1): 23–31 (apenas leitura)
    • Biologics for the primary care physician: Review and treatment of psoriasis. https://doi.org/10.1016/j.disamonth.2018.06.001 (apenas leitura)
  • Aula 08 - Metas terapêuticas do tratamento da Psoríase em placas
    • Videoaula 08 - Metas terapêuticas do Tratamento da Psoríase em placas
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Consenso Brasileiro de Psoríase 2012 (baixável)
    • Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155-157 (apenas leitura)
    • Secukinumab for treating plaque psoriasis. Expert Opinion on Biological Therapy. 2016; 16: 119-128 (apenas leitura)
    • Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016;75:77-82 (apenas leitura)
    • European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. JEADV 2015;29:2277-2294 (apenas leitura)
  • Aula 09 - Imunopatogênese da Psoríase em placas
    • Videoaula 09 - Imunopatogênese da Psoríase
    • Psoriasis as a barrier disease. Dermatologica Sinica. 2015;33: 64-69 (baixável)
    • Better Understanding the Immunopathogenesis of Psoriasis. Clin Res Dermatol Open Access 2017; 4(1):1-3 (baixável)
    • Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201:1605-1613 (baixável)
    • The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. doi: 10.3389/fimmu.2018.01682 (baixável)
    • The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. doi: 10.3389/fimmu.2018.01549 (baixável)
    • Psoriatic Arthritis. N Engl J Med.2017;376:957-970 (apenas leitura)
    • Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? doi:10.1136/annrheumdis-2018-213654 (baixável)
    • Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. Clinic Rev Allerg Immunol. 2018; 55:295–311 (apenas leitura)
    • Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci 2018; 19(1). pii: E179. doi: 10.3390/ijms19010179 (baixável)
  • Aulas 10 e 11- Artrite Psoriásica: definições e considerações importantes (aula 10) e Artrite Psoriásica: entesite, alterações ósseas e comprometimento ungueal (aula 11)
    • Videoaula 10 - Artrite psoriásica: definição e considerações importantes
    • Videoaula 11 - Artrite Psoriásica: entesite, alterações ósseas e comprometimento ungueal
    • Recomendações sobre diagnóstico e tratamento da espondilite anquilosante. Rev Bras Reumatol. 2013;53(3):242–257 (baixável)
    • Psoriatic Arthritis. N Engl J Med.2017;376:957-970 (apenas leitura)
    • Etiology and Pathogenesis of Psoriatic Arthritis. Dis Clin N Am. 2015;41:643–663 (apenas leitura)
    • Artrite psoriásica: entidade clínica distinta da psoríase? Rev Bras Reumatol. 2012;52(4):623-638 (baixavel)
    • Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68:1060-1071 (baixável)
    • Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64 (baixável)
    • Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74 (baixável)
    • Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. https://doi.org/10.1038/s41584-019-0175-0 (apenas leitura)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
    • Enthesitis: from pathophysiology to treatment. doi:10.1038/nrrheum.2017.188 (apenas leitura)
    • Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35–43 (apenas leitura)
    • Nail Psoriasis: A Review of Treatment Options. Drugs. 2016;76:675-705 (baixável)
  • Aulas 12 e 13 - Artrite Psoriásica: dactilite (aula 12); Artrite Psoriásica: artrite periférica e comprometimento axial (aula 13)
    • Videoaula 12 - Dactilite
    • Videoaula 13 - Artrite Psoriásica: artrite periférica e comprometimento axial
    • Pathophysiology, assessment and treatment of psoriatic dactylitis. https://doi.org/10.1038/s41584-018-0147-9 (apenas leitura)
    • Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64 (baixável)
    • Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74 (baixável)
    • Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. Clin Dermatol.2018;36:551–560 (apenas leitura)
    • Psoriatic Arthritis. N Engl J Med.2017;376:957-970 (apenas leitura)
    • Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. JEADV. 2014;28(Suppl. 5):27–32 (baixável)
    • Psoriatic Synovitis: Singularity and Potential Clinical Implications. doi: 10.3389/fmed.2019.00014 (baixável)
    • Artrite psoriásica: entidade clínica distinta da psoríase? Rev Bras Reumatol. 2012;52(4):623-638 (baixavel)
    • Conceitos atuais e relevantes sobre artrite Psoriásica. Rev Bras Reumatol 2012;52(1):92-106 (baixável)
  • Aulas 14 e 15 - Artrite Psoríásica: Diagnóstico e Tratamento (aula 14) e Questionários de screening (aula 15)
    • Videoaula 14 - Diagnóstico e Tratamento da Artrite Psoriásica
    • Videoaula 15 - Questionários de Screening da Artrite Psoriásica
    • Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. Clin Dermatol.2018;36:551–560 (apenas leitura)
    • Psoriatic Arthritis. N Engl J Med.2017;376:957-970 (apenas leitura)
    • 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthrit Care Res. 2019;71:2–29 (baixável)
    • PCDT da Artrite Psoriásica, Ministério da Saúde, 2018. https://portalarquivos2.saude.gov.br/images/pdf/2018/novembro/09/PCDT-Artrite-Psoriaca-22-10-2018.pdf (baixável)
    • Certolizumabe pegol para o tratamento da artrite Psoriásica. Relatório de Recomendação, Ministério da Saúde, novembro de 2019. http://conitec.gov.br/images/Relatorios/2019/Relatorio_Certolizumabe_ArtritePsoriasica.pdf (baixável)
    • Semantic and psychometric validation of the Brazilian Portuguese version (PASE-P) of the Psoriatic Arthritis Screening and Evaluation questionnaire. https://doi.org/10.1371/journal.pone.0205486 (baixável)
    • Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). Arch Dermatol Res (2019). https://doi.org/10.1007/s00403-019-02013-9 (apenas leitura)
  • Aula 16 - Avaliação do paciente antes e durante o tratamento da Psoríase com Biológico
    • Videoaula 16 - Avaliação do paciente antes e durante o tratamento Biológico
    • Position statement for the management of comorbidities in psoriasis. JEADV. 2018;32:2058–2073 (apenas leitura)
    • Manual de Recomendações para o Controle da Tuberculose no Brasil - Ministério da Saúde, 2ª ed, 2019 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
    • Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88-97e5 (apenas leitura)
    • Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews 2015;14:503-09 (apenas leitura)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics. 2010; 49:493–507 (apenas leitura)
    • Portaria sobre novas regras de prescrição de medicamento de alto custo (LME) (baixável)
  • Aula 17 - Tuberculose: considerações importantes
    • Videoaula 17 - Tuberculose: considerações importantes
    • Tuberculosis. doi:10.1038/nrdp.2016.76 (apenas leitura)
    • Manual de Recomendações para o Controle da Tuberculose no Brasil - Ministério da Saúde, 2ª ed, 2019 (baixável)
    • Infecção latente por tuberculose em pacientes com doenças reumatológicas. J Bras Pneumol. 2019;45(2):e20190023 (baixável)
    • Human genetics of tuberculosis: a long and winding road. www.dx.doi.org/10.1098/rstb.2013.0428 (baixável)
    • The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-1206 (baixável)
    • Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real‐world data from 18 Japanese facilities. J Dermatol. 2020;47(2):128-132 (apenas leitura)
  • Aulas 18 e 19: Screening da Tuberculose no Brasil (aula 18) e Tratamento da TBL no Brasil (aula 19)
    • Videoaula 18 - Screening da Tuberculose no Brasil
    • Videoaula 19 - Tratamento da Tuberculose Latente no Brasil
    • Manual de Recomendações para o Controle da Tuberculose no Brasil - Ministério da Saúde, 2ª ed, 2019 (baixável)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Infecção latente por tuberculose em pacientes com doenças reumatológicas. J Bras Pneumol. 2019;45(2):e20190023 (baixável)
    • Diretrizes Clínicas na Saúde Suplementar. Tuberculose infecção latente: diagnóstico, 2011 (baixável)
    • Protocolo de vigilância da infecção latente pelo Mycobacterium tuberculosis no Brasil, Ministério da Saúde, 2018 (baixável)
    • British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol.2017;177:628–636 (baixável)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
  • Aula 20: Indicações dos Biológicos no tratamento da Psoríase em placas no Brasil
    • Videoaula 20 - Indicações dos Biológicos no Tratamento da Psoríase em placas
    • Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics. 2010; 49:493–507 (apenas leitura)
    • Consenso Brasileiro de Psoríase 2012 (baixável)
    • Diagnostic and therapeutic guidelines for plaque psoriasis – Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):S76-107 (baixável)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
  • Aula 21: Inibidores de TNF-alfa aprovados no Brasil para o tratamento da Psoríase: estruturas moleculares, posologias e mecanismos de ação
    • Videoaula 21 - Inibidores de TNF no Tratamento da Psoríase em placas
    • Bula do Adalimumabe (Humira)
    • Bula do Infliximabe (Remicade)
    • Bula do Etanercepte (Enbrel - 25 mg)
    • Bula do Etanercepte (Enbrel - PFS)
    • Bula do Certolizumabe pegol (Cimzia)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. doi: 10.3389/fimmu.2019.00382 (baixável)
    • Tumor Necrosis Factor-Alpha Inhibitory Therapy for NonInfectious Autoimmune Uveitis. DOI:10.5772/intechopen.82800 (baixável)
    • Better Understanding the Immunopathogenesis of Psoriasis. Clin Res Dermatol Open Access 2017; 4(1):1-3 (baixável)
    • Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215–1228 (baixável)
    • Mechanism of action of the biologics used in the treatment of plaque psoriasis. Clin Res Dermatol Open Access 4(1):1-3 (baixável)
  • Aula 22 - Eficácia dos inibidores de TNF-alfa aprovados para o Tratamento da Psoríase em placas no Brasil
    • Videoaula 22 - Eficácia dos inibidores de TNF-alfa (metanálises que comparam adalimumabe, infliximabe e etnercepte), estudo CIMPACT (certolizumabe vs. placebo e etanercepte)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. JEADV. 2014; 28:1633–1653 (apenas leitura)
    • Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle. www.dx.doi.org/10.1155/2014/862851 (baixável)
    • Drug survival of biologic treatments in psoriasis: a systematic review. DOI: 10.1080/09546634.2017.1398393 (apenas leitura)
    • Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015; 172:244–52 (apenas leitura)
    • Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519 (baixável)
    • Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JEADV. 2016: 30:1148-58 (baixável)
    • ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066-72 (apenas leitura)
    • Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632-40 (baixável)
    • Drug survival of biologics in treating psoriasis: a meta-analysis of realworld evidence. DOI:10.1038/s41598-018-34293-y (baixável)
    • Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79:266-76 (baixável)
  • Aula 23 - Inibidores de interleucinas aprovados no Brasil para o tratamento da Psoríase: estruturas moleculares, posologias e mecanismos de ação
    • Videoaula 23 - Inibidores de Interleucinas: estruturas moleculares, posologias e mecanismos de ações
    • Bula do Ustequinumabe (Stelara)
    • Bula do Secuquinumabe (Cosentyx)
    • Bula do Ixequizumabe (Taltz)
    • Bula do Guselcumabe (Tremfya)
    • Bula do Risanquizumabe (Skyrizi)
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Better Understanding the Immunopathogenesis of Psoriasis. Clin Res Dermatol Open Access 2017; 4(1):1-3 (baixável)
    • Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201:1605-1613 (baixável)
    • Mechanism of action of the biologics used in the treatment of plaque psoriasis. Clin Res Dermatol Open Access 4(1):1-3 (baixável)
    • Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci 2018; 19(1). pii: E179. doi: 10.3390/ijms19010179 (baixável)
    • Th17 cell development: from the cradle to the grave. Immunol Rev 2013; 252: 78–88 (apenas leitura)
    • Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis 2018; 9: 111–119 (baixável)
    • Gut-Busters: IL-17 Ain’t Afraid of No IL-23. http://dx.doi.org/10.1016/j.immuni.2015.10.001 (baixável)
  • Aulas 24 e 25 - Eficácia dos Inibidores de Interleucinas aprovados para o tratamento da Psoríase em placas no Brasil
    • Videoaula 24 - Eficácia dos Inibidores de Interleucinas (parte I)
    • Videoaula 25 - Eficácia dos Inibidores de Interleucinas (parte II)
    • Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. N Engl J Med. 2010;362:118-28 (ACCEPT) – apenas leitura
    • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400-409 (CLEAR) - baixável
    • Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study (baixável)
    • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76:405-17 (VOYAGE 1) - baixável
    • Efficacy and safety of guselkumab, na anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatorecontrolled VOYAGE 2 trial. J Am Acad Dermatol 2017;76:418-31 (VOYAGE 2) -baixável
    • Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. http://dx.doi.org/10.1016/S0140-6736(19)30952-3 (apenas leitura)
    • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. http://dx.doi.org/10.1016/S0140-6736(18)31713-6 (apenas leitura)
    • Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. www.dx.doi.org/10.1016/S0140-6736(19)31773-8 (apenas leitura)
    • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol.2017;76:60-9 (baixável)
    • How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis. www.doi.org/10.1080/09546634.2018.1510174 (apenas leitura)
    • Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE 14(8): e0220868. https://doi.org/10.1371/journal.pone.0220868 (baixável)
    • Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). JEADV. 2018;32:1507–1514 (baixável)
    • Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.JAMA Dermatol. Published online February 5, 2020. doi:10.1001/jamadermatol.2019.4029 (apenas leitura)
    • Secukinumab for treating plaque psoriasis. Expert Opinion on Biological Therapy. 2016; 16: 119-128 (apenas leitura)
  • Aula 26 - Eficácia dos Biológicos (aprovados para o tratamento da Psoríase) na Artrite Psoriásica
    • Videoaula 26 - Eficácia dos Biológicos na Artrite Psoriásica
    • Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther. 2013;38:286–93 (baixável)
    • Indirect comparisons of the efficacy of biological agentes in patients with psoriatic arthritis with na inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis. Semin Arthritis Rheum. 2016; 45:428–438 (apenas leitura)
    • Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64 (baixável)
    • Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Meta-analysis. DOI: https://doi.org/10.3899/jrheum.180797 (apenas leitura)
    • Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48:632-637 (apenas leitura)
    • Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? doi:10.1136/annrheumdis-2018-213654 (baixável)
  • Aula 27 - Contraindicações dos Biológicos aprovados para o Tratamento da Psoríase em placas no Brasil
    • Videoaula 27 - Contraindicações dos Biológicos no Tratamento da Psoríase em placas
  • Aula 28 - Biológicos no Tratamento da Psoríase: efeitos adversos mais frequentes
    • Videoaula 28 - Efeitos Adversos mais comuns dos Biológicos usados no Tratamento da Psoríase
    • Guia – Glossário da Resolução RDC Nº04/2009 - ANVISA (baixável)
    • Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441-1448 (apenas leitura)
    • Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013; 168:844–854 (baixável)
    • Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524 (baixável)
    • Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-9 (apenas leitura)
    • Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews 2015;14:503-09 (apenas leitura)
    • Safety of biologics in psoriasis. J Dermatol. 2018;45:279-86 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • Candida infections and interleukin‐17 inhibitors used in dermatology. Br J Dermatol. 2017;177:47–62 (apenas leitura)
    • PCDT de Hepatite Autoimune, Ministério da Saúde, 2018 (baixável)
    • European S3-guidelines on the systemic treatment of psoriasis vulgaris. doi: 10.1111/j.1468-3083.2009.03389.x (baixável)
    • European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC (apenas leitura)
    • Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. doi: 10.3389/fimmu.2018.02746 (baixável)
  • Aula 29 - Biológicos no tratamento da Psoríase: efeitos adversos incomuns e raros
    • Videoaula 29 - Efeitos Adversos incomuns e raros com os Biológicos usados no Tratamento da Psoríase
    • Safety of biologics in psoriasis. J Dermatol. 2018;45:279-86 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073-113 (baixável)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
    • Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews 2015;14:503-09 (apenas leitura)
    • Manual de Recomendações para o Controle da Tuberculose no Brasil - Ministério da Saúde, 2ª ed, 2019 (baixável)
  • Aula 30 - Biológicos no tratamento da Psoríase: eventos adversos graves
    • Videoaula 30 - Efeitos Adversos Graves dos Biológicos usados no Tratamento da Psoríase
    • Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther (2020) 37:364–380. www.doi.org/10.1007/s12325-019-01145-8 (baixável)
    • Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-9 (apenas leitura)
    • Secukinumab sustains good efficacy and favourable safetyin moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177:1033–1042 (baixável)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol. 2017;76:639-647 (apenas leitura)
    • Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol. 2018;179:863-71 (apenas leitura)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
  • Aula 31 - Biológicos no Tratamento da Psoríase e Cirurgias Eletivas
    • Videoaula 31 - Biológicos e Cirurgias Eletivas
    • From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75:798-805 (apenas leitura)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
    • The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. JEADV. 2016; 30: 86-91 (apenas leitura)
    • Manejo dos pacientes em situações especiais (Ana Paula Galli Sanchez, 2019)
  • Aula 32 - Biológicos no Tratamento da Psoríase e Vacinação
    • Videoaula 32 - Biológicos no Tratamento da Psoríase e Vacinação
    • Calendários de vacinação SBIm pacientes especiais – 2019-2020 (baixável)
    • Guia de Imunização SBIm/ASBAI – Asma, Alergia e Imunodeficiências 2015-2016 (baixável)
    • From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol 2013;69:1003-13 (apenas leitura)
    • Folder CRIE, Ministério da Saúde, 2011 (baixável)
    • Manual dos Centros de Referência para Imunobiológicos Especiais, Ministério da Saúde 2014 (baixável)
    • Manual dos Centros de Referência para Imunobiológicos Especiais, Ministério da Saúde 2019 (baixável)
    • Manejo dos pacientes em situações especiais (Ana Paula Galli Sanchez, 2019)
  • Aula 33 - Biológicos no Tratamento da Psoríase: Gestação e Amamentação
    • Videoaula 33 - Biológicos no Tratamento da Psoríase, Gestação e Amamentação
    • Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014;70:401.e1-14 (apenas leitura)
    • Safety of dermatologic medications in pregnancy and lactation. Part II. Lactation. J Am Acad Dermatol 2014;70:417.e1-10 (apenas leitura)
    • British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol.2017;177:628–636 (baixável)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
    • FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol. 2015;194:4595-4603 (baixável)
    • Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233 (baixável)
    • Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890-1896 (baixável)
    • Manejo dos pacientes em situações especiais (Ana Paula Galli Sanchez, 2019)
  • Aulas 34 a 36 - Biológicos no Tratamento da Psoríase e Infecção pelo Vírus da Hepatite B (aula 34); Infecção pelo Vírus da Hepatite C e HIV (aula 35); Retratamento (aula 36)
    • Videoaula 34 - Biológicos no tratamento da Psoríase e Hepatite B
    • Videoaula 35 - Considerações sobre uso Biológicos nos pacientes com Hepatite C e HIV positivos
    • Videoaula 36 - Retratamento e Troca do Biológico na Psoríase
    • From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70(1):178-86 (apenas leitura)
    • Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88-97e5 (apenas leitura)
    • Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018;19:1–13 (apenas leitura)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
    • Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016; 22(28): 6444-6455 (baixável)
    • PCDT da Hepatite C, Ministério da Saúde, 2019 (baixável)
    • A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. JEADV. 2014;28: 438–453 (baixável)
    • Manejo dos pacientes em situações especiais (Ana Paula Galli Sanchez, 2019)
  • Aula 37 - Como escolher o Biológico para o Tratamento da Psoríase em placas
    • Videoaula 37 - Como escolher o Biológico?
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Biologic Therapy in Psoriasis: Navigating the Options. Cutis. 2018;102(suppl 5):13-17 (baixável)
    • Psoriasis: Which therapy for which patient. J Am Acad Dermatol. 2019; 80:43-53 (baixável)
    • Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? doi:10.1136/annrheumdis-2018-213654 (baixável)
    • Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018;19:1–13 (apenas leitura)
    • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72 (baixável)
  • Aulas 38 e 39 - Indicações do Tratamento Biológico de acordo com o PCDT da Psoríase de 2019 (aula 38) e Prescrição de Biológico de acordo com o PCDT da Psoríase de 2019 (aula 39)
    • Videoaula 38 - Indicações dos Biológicos no Tratamento da Psoríase de acordo com o PCDT de 2019
    • Videoaula 39: Prescrição de Biológico pelo SUS
    • PCDT da Psoríase, Ministério da Saúde, 2019 (baixável)
    • Portaria sobre novas regras de prescrição de medicamento de alto custo (LME) (baixável)
  • Aula 40 - Considerações finais
    • Videoaula 40 - Considerações finais
    • Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. Clinic Rev Allerg Immunol. 2018;55:295–311 (apenas leitura)
    • Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. J Aesthetic Dermatol. 2019;12(6):46–54 (baixável)
    • Position statement for the management of comorbidities in psoriasis. JEADV. 2018;32:2058–2073 (apenas leitura)
    • Psoríase: comorbidades clássicas e emergentes. An Bras Dermatol. 2015;90(1): 08-19 (apenas leitura)

Descrição do curso

Os Biológicos vêm revolucionando o tratamento da Psoríase nos últimos anos. São medicamentos eficazes e seguros, porém de custo elevado, estando no Brasil indicados para o tratamento da Psoríase "moderada a grave", refratária ou intolerante aos tratamentos convencionais. São terapias alvo-específicas e, diferentemente dos tratamentos sistêmicos tradicionais, não produzem toxicidade cumulativa em órgãos-alvo.

Muitos médicos já utilizam os Biológicos no tratamento da Psoríase, enquanto outros preferem não utilizar esses medicamentos por não dominarem seus mecanismos de ação e possíveis efeitos adversos. 

Independentemente de prescrever ou não os Biológicos, é importante que os dermatologistas conheçam suas indicações e compreendam a sua importância no arsenal terapêutico da Psoríase. Pensando em facilitar o estudo do médico, elaboramos uma série de videoaulas curtas (microlearnings), que resumem as informações mais relevantes sobre a Psoríase em placas e seu tratamento com os Biológicos.

Apesar de as aulas serem objetivas, as principais referências bibliográficas citadas ficam disponíveis na plataforma, o que permite ao médico, se desejar, aprofundar seu estudo em temas específicos. 

Este curso é útil para os médicos prescritores de Biológicos revisarem os conteúdos abordados, destinando-se também aos médicos que atendem pacientes com psoríase e desejam conhecer e compreender melhor a importância dos Biológicos no seu tratamento.

O curso contou com o APOIO EDUCACIONAL da ABBVIE, NOVARTIS e JANSSEN-CILAG e ficou DISPONÍVEL GRATUITAMENTE AOS MÉDICOS na plataforma da Dermato Brasil de 02/03/2020 a 31/05/2020. 

Todas as videoaulas foram elaboradas pela Dra Ana Paula Galli Sanchez e gravadas em janeiro de 2020.

 

Objetivos

Sintetizar as principais informações sobre o “Tratamento da Psoríase com Biológicos” em aulas curtas e objetivas. 

O médico pode assistir apenas às videoaulas que abordam os temas de seu interesse ou, se preferir, pode fazer uma revisão mais ampla do assunto, assistindo às aulas em sequência.


Para quem é indicado

Médicos que atendem pacientes com Psoríase.

Professores

Ana Paula Galli Sanchez

CRM 81979-SP

Dermatologista e Mestra pela FMUSP

CV lattes: http://lattes.cnpq.br/0039389175184343

[email protected]

Inscreva-se já